MET and hepatocellular carcinoma: Conversely, HCC cells sometimes compensate by accelerating autophagy flux to enhance their own growth and resist the anti-tumor effects of HGF-MET kinase-targeted drugs, such as Onartuzumab (Genentech) and Tivantinib (ArQule).